ReP USP - Resultado da busca

Artigo de periodico
NSC305787, a pharmacological ezrin inhibitor, exhibits antineoplastic activity in pancreatic cancer cells (2022)
Silva, Jean Carlos Lipreri da ; Carvalho, Maria Fernanda Lopes; Miranda, Lívia Bassani Lins De ; Almeida, Bruna Oliveira de ; Lima, Keli Cristina de; Machado Neto, João Agostinho
Fonte: Investigational New Drugs. Unidade: ICB
Assuntos: FARMACOLOGIA, ANTINEOPLÁSICOS, CÉLULAS CULTIVADAS DE TUMOR, NEOPLASIAS PANCREÁTICAS, COMPOSTOS AROMÁTICOS, CITOESQUELETO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SILVA, Jean Carlos Lipreri da et al. NSC305787, a pharmacological ezrin inhibitor, exhibits antineoplastic activity in pancreatic cancer cells. Investigational New Drugs, p. 1-10, 2022Tradução . . Disponível em: https://doi.org/10.1007/s10637-022-01249-z. Acesso em: 26 jul. 2024.
APA
Silva, J. C. L. da, Carvalho, M. F. L., Miranda, L. B. L. D., Almeida, B. O. de, Lima, K. C. de, & Machado Neto, J. A. (2022). NSC305787, a pharmacological ezrin inhibitor, exhibits antineoplastic activity in pancreatic cancer cells. Investigational New Drugs, 1-10. doi:10.1007/s10637-022-01249-z
NLM
Silva JCL da, Carvalho MFL, Miranda LBLD, Almeida BO de, Lima KC de, Machado Neto JA. NSC305787, a pharmacological ezrin inhibitor, exhibits antineoplastic activity in pancreatic cancer cells [Internet]. Investigational New Drugs. 2022 ; 1-10.[citado 2024 jul. 26 ] Available from: https://doi.org/10.1007/s10637-022-01249-z
Vancouver
Silva JCL da, Carvalho MFL, Miranda LBLD, Almeida BO de, Lima KC de, Machado Neto JA. NSC305787, a pharmacological ezrin inhibitor, exhibits antineoplastic activity in pancreatic cancer cells [Internet]. Investigational New Drugs. 2022 ; 1-10.[citado 2024 jul. 26 ] Available from: https://doi.org/10.1007/s10637-022-01249-z
Artigo de periodico
Phenformin increases early hematopoietic progenitors in the Jak2V617F murine model (2022)
Silva, Antônio Bruno Alves; Fenerich, Bruna Alves ; Fonseca, Natasha Peixoto ; Fernandes, Jaqueline Cristina; Silva, Juan Luiz Coelho da ; Martins, Diego Antonio Pereira ; Bianco, Thiago Mantello ; Scheucher, Priscila Santos ; Rego, Eduardo Magalhães ; Chahud, Fernando ; Machado Neto, João Agostinho ; Pontes, Lorena Lôbo de Figueiredo ; Traina, Fabiola
Fonte: Investigational New Drugs. Unidades: FMRP, FM, ICB
Assuntos: FARMACOLOGIA, CÉLULAS CULTIVADAS DE TUMOR, ANTIDIABÉTICOS (HIPOGLICEMIANTES), HEMATOPOESE, CÉLULAS SANGUÍNEAS, CÉLULAS-TRONCO, DOENÇAS HEMATOLÓGICAS, POLICITEMIA, PLAQUETAS SANGUÍNEAS, ANTINEOPLÁSICOS, CAMUNDONGOS, MODELOS ANIMAIS DE DOENÇAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SILVA, Antônio Bruno Alves et al. Phenformin increases early hematopoietic progenitors in the Jak2V617F murine model. Investigational New Drugs, p. 1-10, 2022Tradução . . Disponível em: https://doi.org/10.1007/s10637-022-01212-y. Acesso em: 26 jul. 2024.
APA
Silva, A. B. A., Fenerich, B. A., Fonseca, N. P., Fernandes, J. C., Silva, J. L. C. da, Martins, D. A. P., et al. (2022). Phenformin increases early hematopoietic progenitors in the Jak2V617F murine model. Investigational New Drugs, 1-10. doi:10.1007/s10637-022-01212-y
NLM
Silva ABA, Fenerich BA, Fonseca NP, Fernandes JC, Silva JLC da, Martins DAP, Bianco TM, Scheucher PS, Rego EM, Chahud F, Machado Neto JA, Pontes LL de F, Traina F. Phenformin increases early hematopoietic progenitors in the Jak2V617F murine model [Internet]. Investigational New Drugs. 2022 ; 1-10.[citado 2024 jul. 26 ] Available from: https://doi.org/10.1007/s10637-022-01212-y
Vancouver
Silva ABA, Fenerich BA, Fonseca NP, Fernandes JC, Silva JLC da, Martins DAP, Bianco TM, Scheucher PS, Rego EM, Chahud F, Machado Neto JA, Pontes LL de F, Traina F. Phenformin increases early hematopoietic progenitors in the Jak2V617F murine model [Internet]. Investigational New Drugs. 2022 ; 1-10.[citado 2024 jul. 26 ] Available from: https://doi.org/10.1007/s10637-022-01212-y
Artigo de periodico
STMN1 is highly expressed and contributes to clonogenicity in acute promyelocytic leukemia cells (2021)
Vicari, Hugo Passos ; Silva, Juan Luiz Coelho da ; Martins, Diego Antonio Pereira ; Araujo, Antônio Roberto Lucena de ; Lima, Keli Cristina de ; Silva, Jean Carlos Lipreri da ; Scheucher, Priscila Santos ; Koury, Luisa C.; Melo, Raul A. de ; Bittencourt, Rosane; Pagnano, Katia ; Nunes, Elenaide ; Fagundes, Evandro Maranhão ; Kerbauy, Fabio; Pontes, Lorena Lobo de Figueiredo ; Costa-Lotufo, Letícia Veras ; Rego, Eduardo Magalhães ; Traina, Fabiola ; Machado Neto, João Agostinho
Fonte: Investigational New Drugs. Unidades: FMRP, ICB, FM
Assuntos: FARMACOLOGIA, CÉLULAS SANGUÍNEAS, CLONAGEM, LEUCEMIA MIELOIDE AGUDA, ONCOPROTEÍNAS, CÉLULAS MIELOIDES, CICLO CELULAR, HEMATOPOESE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
VICARI, Hugo Passos et al. STMN1 is highly expressed and contributes to clonogenicity in acute promyelocytic leukemia cells. Investigational New Drugs, p. 1-15, 2021Tradução . . Disponível em: https://doi.org/10.1007/s10637-021-01197-0. Acesso em: 26 jul. 2024.
APA
Vicari, H. P., Silva, J. L. C. da, Martins, D. A. P., Araujo, A. R. L. de, Lima, K. C. de, Silva, J. C. L. da, et al. (2021). STMN1 is highly expressed and contributes to clonogenicity in acute promyelocytic leukemia cells. Investigational New Drugs, 1-15. doi:10.1007/s10637-021-01197-0
NLM
Vicari HP, Silva JLC da, Martins DAP, Araujo ARL de, Lima KC de, Silva JCL da, Scheucher PS, Koury LC, Melo RA de, Bittencourt R, Pagnano K, Nunes E, Fagundes EM, Kerbauy F, Pontes LL de F, Costa-Lotufo LV, Rego EM, Traina F, Machado Neto JA. STMN1 is highly expressed and contributes to clonogenicity in acute promyelocytic leukemia cells [Internet]. Investigational New Drugs. 2021 ; 1-15.[citado 2024 jul. 26 ] Available from: https://doi.org/10.1007/s10637-021-01197-0
Vancouver
Vicari HP, Silva JLC da, Martins DAP, Araujo ARL de, Lima KC de, Silva JCL da, Scheucher PS, Koury LC, Melo RA de, Bittencourt R, Pagnano K, Nunes E, Fagundes EM, Kerbauy F, Pontes LL de F, Costa-Lotufo LV, Rego EM, Traina F, Machado Neto JA. STMN1 is highly expressed and contributes to clonogenicity in acute promyelocytic leukemia cells [Internet]. Investigational New Drugs. 2021 ; 1-15.[citado 2024 jul. 26 ] Available from: https://doi.org/10.1007/s10637-021-01197-0
Artigo de periodico
NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia (2021)
Ribeiro, Renata Scopim ; Machado Neto, João Agostinho ; Eide, Christopher A. ; Silva, Juan Luiz Coelho da ; Fenerich, Bruna Alves ; Fernandes, Jaqueline Cristina; Scheucher, Priscila Santos ; Stevens, Samantha L. Savage ; Campos, Paula de Melo; Saad, Sara T. Olalla ; Palma, Leonardo de Carvalho ; Pontes, Lorena Lobo de Figueiredo ; Simões, Belinda Pinto ; Rego, Eduardo Magalhães ; Tognon, Cristina E. ; Druker, Brian J. ; Traina, Fabiola
Fonte: Investigational New Drugs. Unidades: ICB, FMRP, FM
Assuntos: FARMACOLOGIA, LEUCEMIA MIELOIDE, INSULINA, ANTINEOPLÁSICOS, PROTEÍNAS QUINASES, CÉLULAS SANGUÍNEAS, PROLIFERAÇÃO CELULAR, APOPTOSE, ONCOGENES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
RIBEIRO, Renata Scopim et al. NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia. Investigational New Drugs, v. 39, n. 3, p. 736-746, 2021Tradução . . Disponível em: https://doi.org/10.1007/s10637-020-01028-8. Acesso em: 26 jul. 2024.
APA
Ribeiro, R. S., Machado Neto, J. A., Eide, C. A., Silva, J. L. C. da, Fenerich, B. A., Fernandes, J. C., et al. (2021). NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia. Investigational New Drugs, 39( 3), 736-746. doi:10.1007/s10637-020-01028-8
NLM
Ribeiro RS, Machado Neto JA, Eide CA, Silva JLC da, Fenerich BA, Fernandes JC, Scheucher PS, Stevens SLS, Campos P de M, Saad STO, Palma L de C, Pontes LL de F, Simões BP, Rego EM, Tognon CE, Druker BJ, Traina F. NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia [Internet]. Investigational New Drugs. 2021 ; 39( 3): 736-746.[citado 2024 jul. 26 ] Available from: https://doi.org/10.1007/s10637-020-01028-8
Vancouver
Ribeiro RS, Machado Neto JA, Eide CA, Silva JLC da, Fenerich BA, Fernandes JC, Scheucher PS, Stevens SLS, Campos P de M, Saad STO, Palma L de C, Pontes LL de F, Simões BP, Rego EM, Tognon CE, Druker BJ, Traina F. NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia [Internet]. Investigational New Drugs. 2021 ; 39( 3): 736-746.[citado 2024 jul. 26 ] Available from: https://doi.org/10.1007/s10637-020-01028-8
Artigo de periodico
AD80, a multikinase inhibitor, exhibits antineoplastic effects in acute leukemia cellular models targeting the PI3K/STMN1 axis (2021)
Carlos, Jorge Antonio Elias Godoy; Lima, Kely; Costa-Lotufo, Letícia Veras ; Leitão, Andrei ; Machado Neto, João Agostinho
Fonte: Investigational New Drugs. Unidades: ICB, IQSC
Assuntos: FARMACOLOGIA, LEUCEMIA, ANTINEOPLÁSICOS, FOSFOPROTEÍNAS, MICROTÚBULOS, CÉLULAS CULTIVADAS DE TUMOR, PROLIFERAÇÃO CELULAR, CITOESQUELETO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CARLOS, Jorge Antonio Elias Godoy et al. AD80, a multikinase inhibitor, exhibits antineoplastic effects in acute leukemia cellular models targeting the PI3K/STMN1 axis. Investigational New Drugs, v. 39, n. 4, p. 1139-1149, 2021Tradução . . Disponível em: https://doi.org/10.1007/s10637-021-01066-w. Acesso em: 26 jul. 2024.
APA
Carlos, J. A. E. G., Lima, K., Costa-Lotufo, L. V., Leitão, A., & Machado Neto, J. A. (2021). AD80, a multikinase inhibitor, exhibits antineoplastic effects in acute leukemia cellular models targeting the PI3K/STMN1 axis. Investigational New Drugs, 39( 4), 1139-1149. doi:10.1007/s10637-021-01066-w
NLM
Carlos JAEG, Lima K, Costa-Lotufo LV, Leitão A, Machado Neto JA. AD80, a multikinase inhibitor, exhibits antineoplastic effects in acute leukemia cellular models targeting the PI3K/STMN1 axis [Internet]. Investigational New Drugs. 2021 ; 39( 4): 1139-1149.[citado 2024 jul. 26 ] Available from: https://doi.org/10.1007/s10637-021-01066-w
Vancouver
Carlos JAEG, Lima K, Costa-Lotufo LV, Leitão A, Machado Neto JA. AD80, a multikinase inhibitor, exhibits antineoplastic effects in acute leukemia cellular models targeting the PI3K/STMN1 axis [Internet]. Investigational New Drugs. 2021 ; 39( 4): 1139-1149.[citado 2024 jul. 26 ] Available from: https://doi.org/10.1007/s10637-021-01066-w
Artigo de periodico
Stathmin 1 is highly expressed and associated with survival outcome in malignant adrenocortical tumours (2020)
Passaia, Bárbara dos Santos; Lima, Keli ; Kremer, Jean Lucas ; Conceição, Barbara Brito da ; Mariani, Beatriz Marinho de Paula ; Silva, Jean Carlos Lipreri da ; Zerbini, Maria Claudia Nogueira ; Fragoso, Maria Candida Barisson Villares ; Machado Neto, João Agostinho ; Lotfi, Claudimara Ferini Pacicco
Fonte: Investigational New Drugs. Unidades: FM, ICB
Assuntos: ANATOMIA, FARMACOLOGIA, CÉLULAS CULTIVADAS DE TUMOR, CARCINOMA, NEOPLASIA ENDÓCRINA MÚLTIPLA, MICROTÚBULOS, FENÓTIPOS, CLONAGEM, ONCOPROTEÍNAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PASSAIA, Bárbara dos Santos et al. Stathmin 1 is highly expressed and associated with survival outcome in malignant adrenocortical tumours. Investigational New Drugs, v. 38, p. 899–908, 2020Tradução . . Disponível em: https://doi.org/10.1007/s10637-019-00846-9. Acesso em: 26 jul. 2024.
APA
Passaia, B. dos S., Lima, K., Kremer, J. L., Conceição, B. B. da, Mariani, B. M. de P., Silva, J. C. L. da, et al. (2020). Stathmin 1 is highly expressed and associated with survival outcome in malignant adrenocortical tumours. Investigational New Drugs, 38, 899–908. doi:10.1007/s10637-019-00846-9
NLM
Passaia B dos S, Lima K, Kremer JL, Conceição BB da, Mariani BM de P, Silva JCL da, Zerbini MCN, Fragoso MCBV, Machado Neto JA, Lotfi CFP. Stathmin 1 is highly expressed and associated with survival outcome in malignant adrenocortical tumours [Internet]. Investigational New Drugs. 2020 ; 38 899–908.[citado 2024 jul. 26 ] Available from: https://doi.org/10.1007/s10637-019-00846-9
Vancouver
Passaia B dos S, Lima K, Kremer JL, Conceição BB da, Mariani BM de P, Silva JCL da, Zerbini MCN, Fragoso MCBV, Machado Neto JA, Lotfi CFP. Stathmin 1 is highly expressed and associated with survival outcome in malignant adrenocortical tumours [Internet]. Investigational New Drugs. 2020 ; 38 899–908.[citado 2024 jul. 26 ] Available from: https://doi.org/10.1007/s10637-019-00846-9
Artigo de periodico
Xanthan gum-based hydrogel containing nanocapsules for cutaneous diphenyl diselenide delivery in melanoma therapy (2020)
Ferreira, Luana Mota; Sari, Marcel Henrique Marcondes; Azambuja, Juliana Hofstatter; Silveira, Elita Ferreira da; Cervi, Verônica Ferrari; Marchiori, Marila Crivellaro Lay; Maria-Engler, Silvya Stuchi ; Wink, Márcia Rosângela; Azevedo, Jéssica Gonçalves; Nogueira, Cristina Wayne; Braganhol, Elizandra; Cruz, Letícia
Fonte: Investigational New Drugs. Unidade: FCF
Assuntos: MELANOMA, NEOPLASIAS CUTÂNEAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FERREIRA, Luana Mota et al. Xanthan gum-based hydrogel containing nanocapsules for cutaneous diphenyl diselenide delivery in melanoma therapy. Investigational New Drugs, v. 38, p. 662-674, 2020Tradução . . Disponível em: https://doi.org/10.1007/s10637-019-00823-2. Acesso em: 26 jul. 2024.
APA
Ferreira, L. M., Sari, M. H. M., Azambuja, J. H., Silveira, E. F. da, Cervi, V. F., Marchiori, M. C. L., et al. (2020). Xanthan gum-based hydrogel containing nanocapsules for cutaneous diphenyl diselenide delivery in melanoma therapy. Investigational New Drugs, 38, 662-674. doi:10.1007/s10637-019-00823-2
NLM
Ferreira LM, Sari MHM, Azambuja JH, Silveira EF da, Cervi VF, Marchiori MCL, Maria-Engler SS, Wink MR, Azevedo JG, Nogueira CW, Braganhol E, Cruz L. Xanthan gum-based hydrogel containing nanocapsules for cutaneous diphenyl diselenide delivery in melanoma therapy [Internet]. Investigational New Drugs. 2020 ; 38 662-674.[citado 2024 jul. 26 ] Available from: https://doi.org/10.1007/s10637-019-00823-2
Vancouver
Ferreira LM, Sari MHM, Azambuja JH, Silveira EF da, Cervi VF, Marchiori MCL, Maria-Engler SS, Wink MR, Azevedo JG, Nogueira CW, Braganhol E, Cruz L. Xanthan gum-based hydrogel containing nanocapsules for cutaneous diphenyl diselenide delivery in melanoma therapy [Internet]. Investigational New Drugs. 2020 ; 38 662-674.[citado 2024 jul. 26 ] Available from: https://doi.org/10.1007/s10637-019-00823-2
Artigo de periodico
Autophagy inhibition potentiates ruxolitinib-induced apoptosis in JAK2V617F cells (2020)
Machado Neto, João Agostinho ; Silva, Juan Luiz Coelho da ; Santos, Fábio Pires de Souza ; Scheucher, Priscila Santos ; Campregher, Paulo Vidal ; Hamerschlak, Nelson ; Rego, Eduardo Magalhães ; Traina, Fabiola
Fonte: Investigational New Drugs. Unidades: ICB, FMRP
Assuntos: FARMACOLOGIA, APOPTOSE, LEUCEMIA MIELOIDE AGUDA, NEOPLASIAS POR TIPO HISTOLÓGICO, ANTIMALÁRICOS, CÉLULAS MIELOIDES, CÉLULAS SANGUÍNEAS, ERITRÓCITOS, MUTAÇÃO GENÉTICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MACHADO NETO, João Agostinho et al. Autophagy inhibition potentiates ruxolitinib-induced apoptosis in JAK2V617F cells. Investigational New Drugs, v. 38, p. 733–745, 2020Tradução . . Disponível em: https://doi.org/10.1007/s10637-019-00812-5. Acesso em: 26 jul. 2024.
APA
Machado Neto, J. A., Silva, J. L. C. da, Santos, F. P. de S., Scheucher, P. S., Campregher, P. V., Hamerschlak, N., et al. (2020). Autophagy inhibition potentiates ruxolitinib-induced apoptosis in JAK2V617F cells. Investigational New Drugs, 38, 733–745. doi:10.1007/s10637-019-00812-5
NLM
Machado Neto JA, Silva JLC da, Santos FP de S, Scheucher PS, Campregher PV, Hamerschlak N, Rego EM, Traina F. Autophagy inhibition potentiates ruxolitinib-induced apoptosis in JAK2V617F cells [Internet]. Investigational New Drugs. 2020 ; 38 733–745.[citado 2024 jul. 26 ] Available from: https://doi.org/10.1007/s10637-019-00812-5
Vancouver
Machado Neto JA, Silva JLC da, Santos FP de S, Scheucher PS, Campregher PV, Hamerschlak N, Rego EM, Traina F. Autophagy inhibition potentiates ruxolitinib-induced apoptosis in JAK2V617F cells [Internet]. Investigational New Drugs. 2020 ; 38 733–745.[citado 2024 jul. 26 ] Available from: https://doi.org/10.1007/s10637-019-00812-5
Artigo de periodico
Design, synthesis and cytotoxicity of the antitumor agent 1-azabicycles for chemoresistant glioblastoma cells (2020)
Oliveira, Mona; Santana, Lourenço Luis Botelho de; Serafim, José Claudio; Santos, Airam Oliveira; Quintino, Michelle Pereira; Correia, José Tiago Menezes; Damasceno, Fábio; Sabino, José Ricardo; Pires, Thiago Rubens Cardim; Coelho, Paulo Lucas Cerqueira; Lopes, Giselle Pinto de Faria; Ulrich, Henning ; Costa, Silvia Lima; Cunha, Silvio
Fonte: Investigational New Drugs. Unidade: IQ
Assuntos: CÉLULAS, GLIOMA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
OLIVEIRA, Mona et al. Design, synthesis and cytotoxicity of the antitumor agent 1-azabicycles for chemoresistant glioblastoma cells. Investigational New Drugs, v. 38, p. 1257–1271, 2020Tradução . . Disponível em: https://doi.org/10.1007/s10637-019-00877-2. Acesso em: 26 jul. 2024.
APA
Oliveira, M., Santana, L. L. B. de, Serafim, J. C., Santos, A. O., Quintino, M. P., Correia, J. T. M., et al. (2020). Design, synthesis and cytotoxicity of the antitumor agent 1-azabicycles for chemoresistant glioblastoma cells. Investigational New Drugs, 38, 1257–1271. doi:10.1007/s10637-019-00877-2
NLM
Oliveira M, Santana LLB de, Serafim JC, Santos AO, Quintino MP, Correia JTM, Damasceno F, Sabino JR, Pires TRC, Coelho PLC, Lopes GP de F, Ulrich H, Costa SL, Cunha S. Design, synthesis and cytotoxicity of the antitumor agent 1-azabicycles for chemoresistant glioblastoma cells [Internet]. Investigational New Drugs. 2020 ; 38 1257–1271.[citado 2024 jul. 26 ] Available from: https://doi.org/10.1007/s10637-019-00877-2
Vancouver
Oliveira M, Santana LLB de, Serafim JC, Santos AO, Quintino MP, Correia JTM, Damasceno F, Sabino JR, Pires TRC, Coelho PLC, Lopes GP de F, Ulrich H, Costa SL, Cunha S. Design, synthesis and cytotoxicity of the antitumor agent 1-azabicycles for chemoresistant glioblastoma cells [Internet]. Investigational New Drugs. 2020 ; 38 1257–1271.[citado 2024 jul. 26 ] Available from: https://doi.org/10.1007/s10637-019-00877-2
Artigo de periodico
A novel proteasome inhibitor acting in mitochondrial dysfunction, ER stress and ROS production (2013)
Maria, Durvanei Augusto; Souza, Jean Gabriel de; Morais, Katia L. P.; Berra, Carolina Maria; Zampolli, Hamilton de Campos; Demasi, Marilene; Simons, Simone Michaela; Saito, Renata de Freitas; Chammas, Roger; Chudzinski-Tavassi, Ana Marisa
Fonte: Investigational New Drugs. Unidade: FM
Assuntos: ESTRESSE, NEOPLASIAS (TERAPIA), MECANISMOS DE CONTROLE CELULAR, ADENOCARCINOMA, APOPTOSE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MARIA, Durvanei Augusto et al. A novel proteasome inhibitor acting in mitochondrial dysfunction, ER stress and ROS production. Investigational New Drugs, v. 31, n. 3, p. 493-505, 2013Tradução . . Disponível em: http://link.springer.com/article/10.1007/s10637-012-9871-1. Acesso em: 26 jul. 2024.
APA
Maria, D. A., Souza, J. G. de, Morais, K. L. P., Berra, C. M., Zampolli, H. de C., Demasi, M., et al. (2013). A novel proteasome inhibitor acting in mitochondrial dysfunction, ER stress and ROS production. Investigational New Drugs, 31( 3), 493-505. doi:10.1007/s10637-012-9871-1
NLM
Maria DA, Souza JG de, Morais KLP, Berra CM, Zampolli H de C, Demasi M, Simons SM, Saito R de F, Chammas R, Chudzinski-Tavassi AM. A novel proteasome inhibitor acting in mitochondrial dysfunction, ER stress and ROS production [Internet]. Investigational New Drugs. 2013 ; 31( 3): 493-505.[citado 2024 jul. 26 ] Available from: http://link.springer.com/article/10.1007/s10637-012-9871-1
Vancouver
Maria DA, Souza JG de, Morais KLP, Berra CM, Zampolli H de C, Demasi M, Simons SM, Saito R de F, Chammas R, Chudzinski-Tavassi AM. A novel proteasome inhibitor acting in mitochondrial dysfunction, ER stress and ROS production [Internet]. Investigational New Drugs. 2013 ; 31( 3): 493-505.[citado 2024 jul. 26 ] Available from: http://link.springer.com/article/10.1007/s10637-012-9871-1
Artigo de periodico
Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III, in patients with advanced solid malignancies (2012)
Hammond-Thelin, Lisa A.; Thomas, Melanie B.; Iwasaki, Michiko; Abbruzzese, James L.; Lassere, Yvonne; Meyers, Christina A.; Hoff, Paulo; Bono, Johann de; Norris, Jody; Matsushita, Hitoshi; Mita, Akira; Rowinsky, Eric K.
Fonte: Investigational New Drugs. Unidade: FM
Assuntos: REAÇÃO EM CADEIA POR POLIMERASE, ANTINEOPLÁSICOS (APLICAÇÕES TERAPÊUTICAS), PROLIFERAÇÃO CELULAR, FARMACODINÂMICA, ESTADIAMENTO DE NEOPLASIAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
HAMMOND-THELIN, Lisa A. et al. Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III, in patients with advanced solid malignancies. Investigational New Drugs, v. 30, n. 1, p. 316-326, 2012Tradução . . Disponível em: http://link.springer.com/article/10.1007/s10637-010-9535-y?null. Acesso em: 26 jul. 2024.
APA
Hammond-Thelin, L. A., Thomas, M. B., Iwasaki, M., Abbruzzese, J. L., Lassere, Y., Meyers, C. A., et al. (2012). Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III, in patients with advanced solid malignancies. Investigational New Drugs, 30( 1), 316-326. doi:10.1007/s10637-010-9535-y
NLM
Hammond-Thelin LA, Thomas MB, Iwasaki M, Abbruzzese JL, Lassere Y, Meyers CA, Hoff P, Bono J de, Norris J, Matsushita H, Mita A, Rowinsky EK. Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III, in patients with advanced solid malignancies [Internet]. Investigational New Drugs. 2012 ; 30( 1): 316-326.[citado 2024 jul. 26 ] Available from: http://link.springer.com/article/10.1007/s10637-010-9535-y?null
Vancouver
Hammond-Thelin LA, Thomas MB, Iwasaki M, Abbruzzese JL, Lassere Y, Meyers CA, Hoff P, Bono J de, Norris J, Matsushita H, Mita A, Rowinsky EK. Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III, in patients with advanced solid malignancies [Internet]. Investigational New Drugs. 2012 ; 30( 1): 316-326.[citado 2024 jul. 26 ] Available from: http://link.springer.com/article/10.1007/s10637-010-9535-y?null

Unidades USP

ReP

Filtros

Unidades USP

Departamento

Autores

Autores USP

Assuntos

Agência de fomento

Afiliação dos autores externos não normalizada